Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: Trans-tissue, sustained local drug-delivery systems

Tatsuya Manabe, Hidenobu Okino, Ryo Maeyama, Kazuhiro Mizumoto, Eishi Nagai, Masao Tanaka, Takehisa Matsuda

研究成果: ジャーナルへの寄稿評論記事

10 引用 (Scopus)

抄録

Local recurrence and hepatic metastasis are still the major causes of death of patients who have undergone resection for pancreatic cancer. To decrease the incidence of local recurrence, we have proposed and devised several trans-tissue and local delivery systems, all of which could be applied immediately after surgery at the resected sites: (1) System I: a drug-loaded photocured gelatinous tissue-adhesive gel (bioactive substance reservoir) that enables the sustained release of a drug, protein, or gene-encoding adenovirus, (2) System II: an anti-cytokine antibody-fixed photocured gelatinous, tissue-adhesive gel (cytokine barrier) that prevents cytokine permeation into the resected tissue, (3) System III: a gene-modified cell sheet that enables the sustained release of a very costly protein produced by gene-transduced cells and (4) System IV: a percutaneous drug-delivery device that enables continuous drug infusion and easy removal from the body. This review article is a summary of our several years of efforts and attempts, which are composed of integrated disciplines including active biomaterials and genetic- and tissue-engineerings, to overcome the recurrence of pancreatic cancer. Here, we outline our proposed strategies and therapeutic devices/materials and discuss their potential therapeutic effectiveness, promises and challenges in the clinical settings.

元の言語英語
ページ(範囲)317-330
ページ数14
ジャーナルJournal of Controlled Release
100
発行部数3
DOI
出版物ステータス出版済み - 12 10 2004

Fingerprint

Drug Delivery Systems
Pancreatic Neoplasms
Tissue Adhesives
Cytokines
Recurrence
Gels
Pharmaceutical Preparations
Equipment and Supplies
Genetic Engineering
Biocompatible Materials
Tissue Engineering
Adenoviridae
Cause of Death
Anti-Idiotypic Antibodies
Proteins
Therapeutics
Neoplasm Metastasis
Liver
Incidence
Genes

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

これを引用

Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection : Trans-tissue, sustained local drug-delivery systems. / Manabe, Tatsuya; Okino, Hidenobu; Maeyama, Ryo; Mizumoto, Kazuhiro; Nagai, Eishi; Tanaka, Masao; Matsuda, Takehisa.

:: Journal of Controlled Release, 巻 100, 番号 3, 10.12.2004, p. 317-330.

研究成果: ジャーナルへの寄稿評論記事

Manabe, Tatsuya ; Okino, Hidenobu ; Maeyama, Ryo ; Mizumoto, Kazuhiro ; Nagai, Eishi ; Tanaka, Masao ; Matsuda, Takehisa. / Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection : Trans-tissue, sustained local drug-delivery systems. :: Journal of Controlled Release. 2004 ; 巻 100, 番号 3. pp. 317-330.
@article{841c2055b68540af83d6a81dc007366a,
title = "Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: Trans-tissue, sustained local drug-delivery systems",
abstract = "Local recurrence and hepatic metastasis are still the major causes of death of patients who have undergone resection for pancreatic cancer. To decrease the incidence of local recurrence, we have proposed and devised several trans-tissue and local delivery systems, all of which could be applied immediately after surgery at the resected sites: (1) System I: a drug-loaded photocured gelatinous tissue-adhesive gel (bioactive substance reservoir) that enables the sustained release of a drug, protein, or gene-encoding adenovirus, (2) System II: an anti-cytokine antibody-fixed photocured gelatinous, tissue-adhesive gel (cytokine barrier) that prevents cytokine permeation into the resected tissue, (3) System III: a gene-modified cell sheet that enables the sustained release of a very costly protein produced by gene-transduced cells and (4) System IV: a percutaneous drug-delivery device that enables continuous drug infusion and easy removal from the body. This review article is a summary of our several years of efforts and attempts, which are composed of integrated disciplines including active biomaterials and genetic- and tissue-engineerings, to overcome the recurrence of pancreatic cancer. Here, we outline our proposed strategies and therapeutic devices/materials and discuss their potential therapeutic effectiveness, promises and challenges in the clinical settings.",
author = "Tatsuya Manabe and Hidenobu Okino and Ryo Maeyama and Kazuhiro Mizumoto and Eishi Nagai and Masao Tanaka and Takehisa Matsuda",
year = "2004",
month = "12",
day = "10",
doi = "10.1016/j.jconrel.2004.09.007",
language = "English",
volume = "100",
pages = "317--330",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection

T2 - Trans-tissue, sustained local drug-delivery systems

AU - Manabe, Tatsuya

AU - Okino, Hidenobu

AU - Maeyama, Ryo

AU - Mizumoto, Kazuhiro

AU - Nagai, Eishi

AU - Tanaka, Masao

AU - Matsuda, Takehisa

PY - 2004/12/10

Y1 - 2004/12/10

N2 - Local recurrence and hepatic metastasis are still the major causes of death of patients who have undergone resection for pancreatic cancer. To decrease the incidence of local recurrence, we have proposed and devised several trans-tissue and local delivery systems, all of which could be applied immediately after surgery at the resected sites: (1) System I: a drug-loaded photocured gelatinous tissue-adhesive gel (bioactive substance reservoir) that enables the sustained release of a drug, protein, or gene-encoding adenovirus, (2) System II: an anti-cytokine antibody-fixed photocured gelatinous, tissue-adhesive gel (cytokine barrier) that prevents cytokine permeation into the resected tissue, (3) System III: a gene-modified cell sheet that enables the sustained release of a very costly protein produced by gene-transduced cells and (4) System IV: a percutaneous drug-delivery device that enables continuous drug infusion and easy removal from the body. This review article is a summary of our several years of efforts and attempts, which are composed of integrated disciplines including active biomaterials and genetic- and tissue-engineerings, to overcome the recurrence of pancreatic cancer. Here, we outline our proposed strategies and therapeutic devices/materials and discuss their potential therapeutic effectiveness, promises and challenges in the clinical settings.

AB - Local recurrence and hepatic metastasis are still the major causes of death of patients who have undergone resection for pancreatic cancer. To decrease the incidence of local recurrence, we have proposed and devised several trans-tissue and local delivery systems, all of which could be applied immediately after surgery at the resected sites: (1) System I: a drug-loaded photocured gelatinous tissue-adhesive gel (bioactive substance reservoir) that enables the sustained release of a drug, protein, or gene-encoding adenovirus, (2) System II: an anti-cytokine antibody-fixed photocured gelatinous, tissue-adhesive gel (cytokine barrier) that prevents cytokine permeation into the resected tissue, (3) System III: a gene-modified cell sheet that enables the sustained release of a very costly protein produced by gene-transduced cells and (4) System IV: a percutaneous drug-delivery device that enables continuous drug infusion and easy removal from the body. This review article is a summary of our several years of efforts and attempts, which are composed of integrated disciplines including active biomaterials and genetic- and tissue-engineerings, to overcome the recurrence of pancreatic cancer. Here, we outline our proposed strategies and therapeutic devices/materials and discuss their potential therapeutic effectiveness, promises and challenges in the clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=9644264016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644264016&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2004.09.007

DO - 10.1016/j.jconrel.2004.09.007

M3 - Review article

C2 - 15567499

AN - SCOPUS:9644264016

VL - 100

SP - 317

EP - 330

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -